Hetero Labs Limited (HLL), as per the credit ratings, is a pharmaceutical company engaged in the business of manufacturing Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDF). HLL’s business areas are spread across APIs, generics, custom pharmaceutical services, and branded generics. The company has a portfolio of over 300 products, encompassing therapeutic categories such as HIV/AIDS, oncology, diabetes, ophthalmology, hepatology, and immunology, among others. HLL has a global presence in over 145 countries. It has manufacturing facilities comprising 15 API units and 23 FDF units, and three R&D centres. HLL has branch offices and manufacturing facilities located in Asia, the Middle East, Europe, Africa, and Australia, among others. It has 450+ APIs and 550+ FDFs. The manufacturing facilities of the company have been approved by the US FDA, WHO, COFEPRIS Mexico, ANVISA-Brazil, NOMA – Norway, and MCC South Africa. It is a part of the Hetero Group.